ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1245

Smoking Might Reduce Odds of Sjӧgren’s Syndrome Among Rheumatoid Arthritis Patients

Sara McCoy1 and Christie Bartels2, 1University of Wisconsin, Madison, 2University of Wisconsin School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Madison, WI

Meeting: ACR Convergence 2020

Keywords: rheumatoid arthritis, Sjögren's Syndrome, Smoking

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2020

Title: Sjögren’s Syndrome Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Smoking increases the risk of many rheumatic disease, including rheumatoid arthritis (RA). Previous studies have identified that current smoking might reduce the risk of primary Sjӧgren’s syndrome (SS), but it remains unknown whether smoking is positively or negatively associated with SS among RA patients. The objective of this cross-sectional study was to examine the relationship between smoking and RA-SS overlap in a large RA cohort.

Methods: Electronic health records from a rural, population-based cohort were screened for RA cohort eligibility. Inclusion criteria include age ≥18 years, at least two RA diagnosis codes from a rheumatologist on distinct dates within a two year period or positive rheumatoid factor or ant-CCP antibody between 1/1/2005 and 12/31/2018. Index date was defined by the first RA diagnosis code.  The baseline period for evaluation of comorbidities and medication use began twelve months before the index date. The independent variable of smoking status was defined as never, current, or past (quit) smoker at or before the index date. The dependent variable of SS was defined by ICD 9 code 710.2.  Descriptive statistics were performed using chi square for categorical and unpaired student’s t-test for continuous variables.  Multivariable logistic regression was performed to determine odds ratios (ORs) of SS as the primary outcome by smoking status. Models were adjusted for age, sex, and race.

Results: Among 1861 patients with RA identified for cohort inclusion, 1296 patients had a reported smoking status available. Current smokers were younger and had lower female predominance than never and past smokers (Table 1). Fewer current smokers had anemia, congestive heart failure, hypertension, hypothyroidism, and renal disease. Descriptive analysis of RA patients with or without SS revealed that SS patients were more likely to be female and less likely to be anemic or smoke (Table 2). Adjusted OR of female sex was positively associated with SS (OR 2.56 [95% Confidence Interval (CI) 1.48-4.73]; Table 3). Current smoking was negatively associated with SS (OR 0.2 [95% CI 0.06-0.68]). Because data on smoking before cohort entry were missing for 565 patients, we repeated analysis on smoking status of patients captured before cohort exit (38 patients missing) and reproduced these results (data not shown).

Conclusion: We report for the first time that RA patients who smoke had 80% lower odds of SS. Previously, studies have shown reduced risk of primary SS in current smokers, supporting our findings. We found female sex in RA had a greater than 2.5 fold association with SS. Our data suggest a negative correlation between smoking and SS among RA patients. Our cross-sectional observational study cannot exclude reverse causality of quitting smoking with SS symptoms. Future studies should prospectively examine pack year dose relationships with overlap RA-SS incidence to further examine risk reduction and causality.


Disclosure: S. McCoy, Bristol-Myers Squibb, 1, Novartis, 1; C. Bartels, Independent Grants for Learning and Change (Pfizer), 2.

To cite this abstract in AMA style:

McCoy S, Bartels C. Smoking Might Reduce Odds of Sjӧgren’s Syndrome Among Rheumatoid Arthritis Patients [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/smoking-might-reduce-odds-of-sj%d3%a7grens-syndrome-among-rheumatoid-arthritis-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/smoking-might-reduce-odds-of-sj%d3%a7grens-syndrome-among-rheumatoid-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology